Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced in taking immuno-oncology products to the clinic.
Accession Therapeutics’ Trocept technology, which is being developed by its Trocept Therapeutics subsidiary, is based on over a decade’s work at the Cardiff University. It has generated exceptional preclinical data and the first drug candidate generated by the Trocept platform is expected to be IND stage by late 2023. The pipeline may be enhanced by Accession Therapeutics through the acquisition of additional intellectual property in due course.
developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumour diversity
how the science works